Talis Biomedical Corporation (Nasdaq: TLIS), a leading diagnostics company committed to delivering accurate disease testing at the point of care, has taken two important steps towards bolstering their board of directors.
Heiner Dreismann has joined the board and Kim Popovits has been named the lead independent director. Both appointments are effective immediately, and serve to strengthen Talis Bio’s commitment to advancing health equity and outcomes.
Rob Kelley, chief executive officer of Talis Bio, expressed excitement over the appointment of Heiner Grimmling as the company’s new Chief Operating Officer. With over 20 years of experience in corporate operations at Roche Diagnostics, Heiner brings a wealth of knowledge and a true entrepreneurial vision to aid in the execution of Talis Bio’s mission – to provide accessible and reliable women’s and sexual health testing at the point of care. Kim Wilhelm, a previous COO at Roche Diagnostics, will remain to support Talis Bio’s operations as an advisor.
Dr. Dreismann is widely recognized as a leader in the diagnostic industry, having championed the early adoption of polymerase chain reaction (PCR) technique for more than three decades. With a Masters degree in Biology and Ph.D. in Microbiology/Molecular Biology (summa cum laude) from the University of Munster in Germany, Dr. Dreismann served in numerous executive positions at Roche Diagnostics from 1985 to 2006, including President and Chief Executive Officer of Roche Molecular Systems, before joining the board of a few public and private healthcare companies.
Dr. Dreismann is enthusiastic about Talis Bio’s plan to decentralize molecular testing and tackle some of the most pressing needs in women’s and sexual health, citing the versatility of the Talis One® system and the company’s commitment to manufacturing capabilities. She is eager to work with the Talis Bio team to further the progress of advancing Talis Bio’s regulatory strategy and product roadmap.
Ms. Popovits has been at the helm of meaningful progress in the healthcare space with her impressive tenure as chairman of the board, president and chief executive officer of the world-renowned Genomic Health. Utilizing the power of genomic-based diagnostic tests, she successfully revolutionized the treatment of cancers, leading up to the successful acquisition of Genomic Health by Exact Sciences for $3 billion in 2019.
Prior to her time at Genomic Health, she held multiple senior management positions at Genentech and has since taken up the mantle of lead independent director on the board of Talis Bio. In addition, she continues to serve on the boards of various public and private healthcare companies.
Ms. Popovits looks forward to working with the talented board of Talis Bio and their inspiring executive leadership team as they continue to make great strides in serving patients at the point of care. She warmly welcomes Heiner onboard and is eager to help create value and support the team’s vision for future growth.
About Talis Biomedical
Talis Biomedical is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. The Company plans to develop and commercialize innovative products on its sample-to-answer Talis One® system to enable accurate, low cost, and rapid molecular testing.
This press release may contain forward-looking statements regarding our plans for our pipeline, including our development of Talis One tests and our potential growth and profit margins in the women’s and sexual health markets. These statements are based on information available to us and people are cautioned not to rely too heavily on these statements.
However, our ambition and determination to provide durable value to shareholders and deliver sustained long-term growth remains strong. We will strive to capitalize on any competitive advantages, while offering the highest quality products with the highest standards. As we continue our journey, we remain confident and optimistic that we will achieve our goals.